Company profile
Bright Peak Therapeutics AG
Bright Peak is developing next-generation engineered cytokines for immuno-oncology indications.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2022
Top 100 Swiss Startup Award 2022
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". Register for more services
Partners
Contributors
